Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-18 pm EDT			5-day change	1st Jan Change
629.68 ^USD	-9.82%		-11.66%	-18.42%

May. 18	US Equity Indexes Off Session Lows as Trump Postpones Iran Attack	MT
May. 18	US Equity Markets Mixed as Investors Weigh Reports of Iran's Updated Peace Proposal	MT

Transcript : Regeneron Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02

Published on 01/12/2026 at 07:00 pm EST - Modified on 01/12/2026 at 08:10 pm EST

S&P Capital IQ

Presenter Speech
Christopher Schott (Analysts)

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Regeneron today. From the company, we have Regeneron's

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

May. 18	US Equity Indexes Off Session Lows as Trump Postpones Iran Attack	MT
May. 18	US Equity Markets Mixed as Investors Weigh Reports of Iran's Updated Peace Proposal	MT
May. 18	Top Midday Decliners	MT
May. 18	US Equity Indexes Mixed, Crude Oil Rises as Iran Reportedly Sends Revised Peace Proposal	MT
May. 18	Canaccord Genuity Cuts Regeneron Pharmaceuticals Price Target to $875 From $1,057, Maintains Buy Rating	MT
May. 18	Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says	MT
May. 18	Regeneron hit by advanced melanoma treatment failing trial
May. 18	Global markets live: Merck, Regeneron, Ford, Lululemon, Brambles…
May. 18	Regeneron drops after skin cancer treatment fails late-stage trial	RE
May. 18	Markets Run Into Higher Yields
May. 18	New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower	MT
May. 18	Regeneron Pharmaceuticals Forms Helicon Research Collaboration With Parabilis Medicines	MT
May. 18	RBC Cuts Price Target on Regeneron Pharmaceuticals to $707 From $762, Keeps Sector Perform Rating	MT
May. 18	Regeneron announces strategic collaboration with Parabilis Medicines to advance novel antibody-Helicon conjugates across multiple therapeutic areas	RE
May. 18	Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $641 From $792	MT